Understanding the Past: How long has Abraxane been around?
•
2 min read
First approved by the U.S. Food and Drug Administration (FDA) on January 7, 2005, for metastatic breast cancer, Abraxane (nab-paclitaxel) has been a key oncology medication for nearly two decades. Its longevity in the field is a testament to its innovative nanoparticle albumin-bound technology, which has addressed key limitations of its predecessor and expanded its use to treat multiple types of solid tumors.
